TRUESHARES

TRUESHARES

Healthcare’s Pulse on Artificial Intelligence

According to a recent survey, 94% of healthcare companies1 claim to use Artificial Intelligence and Machine Learning (AI/ML) in some capacity. The key to leveraging AI/ML in healthcare is data. Human health deals with vast amounts of complex datasets, from images and test results to medical history and genomic data. AI/ML can not only process a lot of complex data, but can analyze it and provide predictions or recommendations at far faster speeds than any human can. The four primary ways AI/ML is utilized in the healthcare industry are for drug discovery, detecting and diagnosing diseases, at-home care and health monitoring, and increased personalization and efficiency. 

It is estimated that it takes eight years and $2 billion2 to develop one drug, which then only has a one in ten chance of being approved. AI can reduce the cost and timeline while helping to discover safer and more effective drugs with a higher likelihood of acceptance. The more drug discovery is improved, the more drugs can be created, and the more revenue a company can potentially make, adding to the valuation1 of the industry as a whole. Since an AI method for predicting a protein structure was discovered, AI/ML has been used to accelerate the drug discovery process, most notably with the development of the COVID-19 mRNA vaccine2. 

AI has also been used to detect COVID-193, along with other diseases and disorders. One study4 found that AI was able to identify skin cancer better than a group of 58 dermatologists. Another group of researchers5 fed images and health data into a machine learning algorithm to diagnose autism spectrum disorder with 95% accuracy. And in 2019, a deep learning algorithm3 outperformed radiologists in detecting lung cancer. A Harvard study4 showed that using AI for diagnostics can reduce costs by 50% and improve health outcomes by 40%. 

AI can also be used at home to help patients self-administer treatments and medications more effectively. One study found that 70% of patients4 don’t take insulin as prescribed. AI also makes health monitoring more convenient and accurate through various Internet of Things devices. While the first AI/ML medical device2 was approved by the FDA in 1995, 24% of medical devices1 today employ some level of AI/ML. 

More than anything, AI can be used to unlock more efficient solutions for patients and doctors alike. For patients, AI can be used to optimize the search for pharmacies, insurance plans, and doctors or otherwise remove barriers1 to navigating the complicated healthcare system. For doctors, AI can help with administrative tasks, freeing up the doctor to spend more time with patients flexing the empathy5 that AI sorely lacks. 

There is significant potential for the breadth of AI technologies to be adopted throughout the industry. The AI healthcare market is projected to grow4 from $11 billion in 2021 to $180 billion by 2030. Those in the best position1 to leverage AI are larger companies with the capital to procure large proprietary datasets and invest in developing and training AI models. 

The TrueShares Technology, Deep Learning, and AI ETF (LRNZ) is designed to provide thematic exposure to a concentrated portfolio or technology companies, including those in the biotechnology and healthcare sectors that are particularly apt at developing or deploying AI technology in the industry. Healthcare and biotech company holdings in LRNZ utilize AI/ML for innovative drug discovery and preventative healthcare, all with far-reaching implications for the future of human health.

  1. https://www.morganstanley.com/ideas/ai-in-health-care-forecast-2023
  2. https://www.goldmansachs.com/intelligence/pages/how-artificial-intelligence-is-accelerating-innovation-in-healthcare.html
  3. https://www.techtarget.com/searchenterpriseai/tip/The-history-of-artificial-intelligence-Complete-AI-timeline
  4. https://www.ibm.com/blog/the-benefits-of-ai-in-healthcare/
  5. https://www.foxnews.com/health/researchers-use-artificial-intelligence-help-diagnose-autism-study

Risks are associated with investing in the healthcare industry and the application of artificial intelligence to the healthcare industry.

Recent Posts

    Request a meeting with our investment team

    433 W. Van Buren Street, 1100-D
    Chicago, IL 60607
    Email: info@true-shares.com
    Phone: 877.774.TRUE

    ©2024, TrueShares, ©2024 TrueMark Investments, LLC. (“TrueMark”).

    Before investing, carefully consider the TrueShares ETFs investment objectives, risks, charges and expenses. Specific information about TrueShares is contained in the prospectus and a summary prospectus, copies of which may be obtained by visiting www.www.true-shares.com. Read the prospectus carefully before you invest.

    An investment in TrueShares is subject to numerous risks, including possible loss of principal. The ETFs are subject to the following principal risks: Authorized Participants, Market Makers, and Liquidity Providers Concentration Risk associated with ETFs; Equity Market Risk; Management Risk; Market Capitalization Risk (Large Cap; Mid Cap, Small Cap Stock); Market Risk; New Fund Risk.

    Individual investors should contact their financial advisor or broker dealer representative for more information on TrueShares ETFs.

    Investment Products and Services are: Not FDIC INSURED / May lose value / No bank guarantee

    All registered investment companies, including TrueShares, are obliged to distribute portfolio gains to shareholders at year-end regardless of performance. Trading in TrueShares ETFs will also generate tax consequences and transaction expenses. The information provided is not intended to be tax advice. Tax consequences of dividend distributions may vary by individual taxpayer.

    TrueShares ETFs are bought and sold through exchange trading at market price, not Net Asset Value (NAV), and are not individually redeemed from the fund. Shares may trade at a premium or discount to their NAV in the secondary market. Brokerage commissions will reduce returns.

    ETF shares may be bought or sold throughout the day at their market price, not their NAV, on the exchange on which they are listed. Shares of ETFs are tradable on secondary markets and may trade either at a premium or a discount to their NAV on the secondary market.

    ETFs trade like stocks, fluctuate in market value and may trade at prices above or below the ETF’s NAV. Brokerage commissions and ETF expenses will reduce returns.

    Fund Intelligence Mutual Fund Industry and ETF Award shortlists and winners are comprised of individuals and firms who have submitted entries or been nominated via the online submission process, as well as through recommendations from leading market participants. Fund Intelligence Mutual Fund Industry and ETF Award judges will use the submitted application material, as well as any uploaded supplemental information, to determine which firm, individual or product they believe to be the most suitable and deserving winners for each category. Fund Intelligence Mutual Fund Industry and ETF Award judges have the discretionary power to move nominations into alternative categories that they think may be more suitable. Fund Intelligence Mutual Fund Industry and ETF Awards were decided by an independent panel of 20 judges with expertise across the asset management space.

    TrueShares ETFs (the “Funds”) are registered with the United States Securities and Exchange Commission under the Investment Company Act of 1940. Foreside Fund Services, LLC is the distributor for the Structured Outcome Funds, LRNZ, ERNZ, FLDZ, DIVZ, RNWZ, and SPCZ.  Paralel Distributors LLC is the distributor for QBER and QBUL.  Foreside Fund Services, LLC, Paralel Distributors LLC, and TrueMark Investments, LLC. are not affiliated.  

    TrueMark Investments, LLC, not an affiliate of Foreside Fund Services, LLC., is the investment advisor to the Funds and receives a fee from the Funds for its services.

    TrueShares ETFs are offered only to United States residents, and information on this site is intended only for such persons. Nothing on this website should be considered a solicitation to buy nor an offer to sell shares of any fund in any jurisdiction where the offer or solicitation would be unlawful under the securities laws of such jurisdiction.